Today’s IPO for Third Harmonic Bio (Nasdaq: THRD) opened for trading at $20.50 after pricing 10,900,000 shares of its common stock at $17 per share, the middle of the expected range. The IPO size was raised from 9,000,000 shares.
Morgan Stanley, Jefferies, Cowen, and Lifesci Capital are acting as underwriters of the offering. The underwriters a 30-day option to purchase up to an additional 1,635,000 shares of common stock at the IPO price.
Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases.